ArticleHealthcare (Basel, Switzerland)2026

Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study.

Olatz Vergniory-Trueba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.